<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392700</url>
  </required_header>
  <id_info>
    <org_study_id>B2019-05201</org_study_id>
    <nct_id>NCT04392700</nct_id>
  </id_info>
  <brief_title>A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection</brief_title>
  <official_title>A Prospective Randomized Controlled Trial of Tenofovir and Entecavir in the Treatment of Long-term Prognosis in Patients With Hepatitis B-related Hepatocellular Carcinoma After Curative Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of Tenofovir and Entecavir in the treatment of Hepatitis
      B-related hepatocellular carcinoma after curative resection in adults. Half of participants
      will receive Tenofovir disoproxil fumarate, while the other half will receive Entecavir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiviral potency significantly differs among various antiviral agents，Entecavir and
      tenofovir disoproxil fumarate are equally recommendedas first-line treatments for patients
      with chronic hepatitis B (CHB). However, it is unclear whether treatment with these drugs is
      associated with equivalent clinical outcomes,especially impacts the risk of HCC recurrence.
      Entecavir and tenofovir disoproxil fumarate have comparable efficacy in achieving surrogate
      end points, including virologic response,but they do by different mechanisms .

      Entecavir, a guanosine nucleoside analogue with activity against HBV reverse transcriptase
      (rt),is efficiently phosphorylated to the active triphosphate form, which has an
      intracellular half-life of 15 hours. By competing with the natural substrate deoxyguanosine
      triphosphate, entecavir triphosphate functionally inhibits all three activities of the HBV
      reverse transcriptase: (1) basepriming, (2) reverse transcription of the negative strand from
      the pregenomic messenger RNA,and (3) synthesis of the positive strand of HBV DNA.

      Tenofovir fumarate is a cyclic nucleoside phosphine diester structural analog of adenosine
      monophosphate. Tenofovir disoproxil fumarate first needs to be converted to tenofovir by
      hydrolysis of the diester, followed by phosphorylation of cellular enzymes to form tenofovir
      diphosphate. Tenofovir diphosphate competes with the natural substrate 5'-deoxyadenosine
      triphosphate for its involvement in the synthesis of viral DNA, which, after entering the
      viral DNA strand, can cause DNA elongation to be blocked due to its lack of 3'-OH
      groups,thereby blocking the replication of the virus. Tenofovir diphosphate is a weak
      inhibitor of mammalian DNA polymerase alpha, beta and mitochondrial DNA polymerase gamma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Anticipated">July 25, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of HCC</measure>
    <time_frame>36 months</time_frame>
    <description>radiologic evidence of tumor recurrence（CT or MRI ） at any time during the following time after liver resection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of overall patients</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">706</enrollment>
  <condition>Hepatocellular Carcinoma Recurrent</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drugs：tenofovir disoproxil fumarate, dose：300mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>drugs：entecavir dose： 0.5 mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate 300mg</intervention_name>
    <description>Take the medicine once a day ，300mg/d</description>
    <arm_group_label>group A</arm_group_label>
    <other_name>Fu Ma Suan Ti Nuo Fu Wei Er Bi Fu Zhi Pian</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir 0.5 mg</intervention_name>
    <description>Take the medicine once a day，0.5 mg/d</description>
    <arm_group_label>group B</arm_group_label>
    <other_name>EnTiKaWeiPian(BoLuDing)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 18 to 70 years

          2. Positive test for hepatitis B surface antigen (HBsAg) and negative tests for
             antibodies to hepatitis C virus (HCV-Ab) or to human immunodeficiency virus

          3. Clinical diagnosis is consistent with HCC and histopathological result of the resected
             specimens being HCC

          4. No previous treatment of HCC and no previous treatment of hepatitis B with nucleoside
             or nucleotide analogues or both; no previous treatment with interferon or other
             immunomodulators

          5. BCLC stage 0, A or a solitary tumor with a diameter &gt;5cm

          6. No extrahepatic metastasisc

          7. No radiologic evidence of invasion into major portal/hepatic venous branches

          8. Good liver function with Child-Pugh Class A or Child - Pugh Class B (If B Child - Pugh
             score ≤7 ) and baseline serum alanine aminotransferase (ALT) level less than 3 times
             the upper limit of normal (reference range &lt;40IU/L), with no history of
             encephalopathy, ascites refractory to diuretics, esophagogastric variceal bleeding

          9. Good renal function (a serum creatinine level&lt;133mmol/L)

         10. Negative resection margin (R0 resection)

         11. Laboratory blood tests : WBC≥≥3.0×10^9/L ; PLT≥75×10^9/L ; Hb≥100g/L Cr&lt;133mmol/L ;
             ALT≤ 150U/L ; AST ≤ 120U/L ; ALB≥30g/L ; TBIL≤34mmol/L INR &lt; 1.5 ; APTT &lt; 18 S

        Exclusion Criteria:

          1. Eligible patients were excluded if they refused to participate

          2. Histopathological result of the resected specimens being not HCC

          3. History of antiviral therapy

          4. History of receive treatment of HCC， include drugs 、radiofrequency ablation
             transcatheter arterial chemoembolization or resection

          5. age﹤ 18 or ﹥70 years

          6. Pregnant or lactating women

          7. Poor liver function and poor renal function

          8. Suffering from other serious acute or chronic physical or mental illness

          9. The following occurred before the study began：Myocardial infarction、 Unstable
             angina、Coronary artery bypass surgery、Cerebrovascular 、 Pulmonary embolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Xu</last_name>
    <phone>86-20-87343115</phone>
    <email>zhouzhg@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongguo Zhou</last_name>
      <email>zhouzhg@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhongguo Zhou</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>antiviral therapy; hepatocellular carcinoma; prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

